| Tchem | Mitogen-activated protein kinase kinase kinase kinase 3 |
May play a role in the response to environmental stress. Appears to act upstream of the JUN N-terminal pathway.
This gene encodes a member of the mitogen-activated protein kinase kinase kinase kinase family. The encoded protein activates key effectors in cell signalling, among them c-Jun. Alternatively spliced transcripts encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Jul 2012]
This gene encodes a member of the mitogen-activated protein kinase kinase kinase kinase family. The encoded protein activates key effectors in cell signalling, among them c-Jun. Alternatively spliced transcripts encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Jul 2012]
Comments
| Disease | Target Count |
|---|---|
| Blastic phase chronic myeloid leukemia | 58 |
| Chronic Myelocytic Leukemia Accelerated Phase | 59 |
| Disease | Target Count | P-value |
|---|---|---|
| lung cancer | 4473 | 3.22173177251051E-5 |
| ovarian cancer | 8492 | 0.00722907280848181 |
| osteosarcoma | 7933 | 0.00781154473353272 |
| ependymoma | 2514 | 0.0303391996431517 |
| intraductal papillary-mucinous neoplasm (IPMN) | 3289 | 0.0308725472050287 |
| Multiple myeloma | 1328 | 0.0449629143629525 |
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| adult-onset Still's disease | 6 | 3.594 | 1.8 |
| Disease | log2 FC | p |
|---|---|---|
| Multiple myeloma | 1.578 | 0.045 |
| ependymoma | 1.100 | 0.030 |
| osteosarcoma | 1.115 | 0.008 |
| intraductal papillary-mucinous neoplasm ... | 1.700 | 0.031 |
| lung cancer | 1.700 | 0.000 |
| ovarian cancer | 1.600 | 0.007 |
| Species | Source |
|---|---|
| Chimp | OMA EggNOG |
| Macaque | OMA EggNOG |
| Mouse | OMA EggNOG Inparanoid |
| Rat | OMA EggNOG Inparanoid |
| Dog | OMA Inparanoid |
| Horse | OMA Inparanoid |
| Cow | OMA Inparanoid |
| Opossum | EggNOG Inparanoid |
| Platypus | OMA EggNOG Inparanoid |
| Anole lizard | OMA Inparanoid |
| Xenopus | OMA Inparanoid |
| C. elegans | OMA EggNOG |
| PMID | Text |
|---|---|
| 23981581 | ITGB3 and MAP4K3 are directly repressed by let-7c, altering the metastatic potential of lung cancer cells. |
| 22898570 | MAP4K3 expression is required for leucine-induced mTORC1 activation in human primary fibroblasts. |
| 22867055 | Significantly higher median frequencies of circulating GLK-expressing T-cells were observed in patients with adult-onset Still's disease (31.85%) than in healthy volunteers (8.93%, P <0.001). |
| 21983831 | enhanced expression in systemic lupus erythematosus |
| 20628086 | Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 20379614 | Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator) |
| 20227368 | Amino acid sufficiency phosphorylates MAP4K3/Ser170, activating mTORC1, but amino acid restriction causes MAP4K3 to interact with PP2A(T61 epsilon), promoting dephosphorylation of Ser170, MAP4K3 inhibition, and, inhibition of mTORC1 signaling. |
| 20200978 | Observational study of gene-disease association. (HuGE Navigator) |
| 19913121 | Observational study of gene-disease association. (HuGE Navigator) |
| 19587239 | MAP4K3 orchestrates activation of BAX via the concerted posttranscriptional modulation of PUMA, BAD, and BIM. |
MNPGFDLSRRNPQEDFELIQRIGSGTYGDVYKARNVNTGELAAIKVIKLEPGEDFAVVQQEIIMMKDCKH 1 - 70 PNIVAYFGSYLRRDKLWICMEFCGGGSLQDIYHVTGPLSELQIAYVSRETLQGLYYLHSKGKMHRDIKGA 71 - 140 NILLTDNGHVKLADFGVSAQITATIAKRKSFIGTPYWMAPEVAAVERKGGYNQLCDLWAVGITAIELAEL 141 - 210 QPPMFDLHPMRALFLMTKSNFQPPKLKDKMKWSNSFHHFVKMALTKNPKKRPTAEKLLQHPFVTQHLTRS 211 - 280 LAIELLDKVNNPDHSTYHDFDDDDPEPLVAVPHRIHSTSRNVREEKTRSEITFGQVKFDPPLRKETEPHH 281 - 350 ELPDSDGFLDSSEEIYYTARSNLDLQLEYGQGHQGGYFLGANKSLLKSVEEELHQRGHVAHLEDDEGDDD 351 - 420 ESKHSTLKAKIPPPLPPKPKSIFIPQEMHSTEDENQGTIKRCPMSGSPAKPSQVPPRPPPPRLPPHKPVA 421 - 490 LGNGMSSFQLNGERDGSLCQQQNEHRGTNLSRKEKKDVPKPISNGLPPTPKVHMGACFSKVFNGCPLKIH 491 - 560 CASSWINPDTRDQYLIFGAEEGIYTLNLNELHETSMEQLFPRRCTWLYVMNNCLLSISGKASQLYSHNLP 561 - 630 GLFDYARQMQKLPVAIPAHKLPDRILPRKFSVSAKIPETKWCQKCCVVRNPYTGHKYLCGALQTSIVLLE 631 - 700 WVEPMQKFMLIKHIDFPIPCPLRMFEMLVVPEQEYPLVCVGVSRGRDFNQVVRFETVNPNSTSSWFTESD 701 - 770 TPQTNVTHVTQLERDTILVCLDCCIKIVNLQGRLKSSRKLSSELTFDFQIESIVCLQDSVLAFWKHGMQG 771 - 840 RSFRSNEVTQEISDSTRIFRLLGSDRVVVLESRPTDNPTANSNLYILAGHENSY 841 - 894 //
| PMID | Year | Title |
|---|---|---|
| 23981581 | 2014 | MicroRNA let-7c inhibits migration and invasion of human non-small cell lung cancer by targeting ITGB3 and MAP4K3. |
| 22898570 | 2013 | Cellular signaling of amino acids towards mTORC1 activation in impaired human leucine catabolism. |
| 22867055 | 2012 | Germinal center kinase-like kinase (GLK/MAP4K3) expression is increased in adult-onset Still's disease and may act as an activity marker. |
| 22814378 | 2012 | N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB. |
| 22223895 | 2012 | Comparative large scale characterization of plant versus mammal proteins reveals similar and idiosyncratic N-?-acetylation features. |
| 21983831 | 2011 | The kinase GLK controls autoimmunity and NF-?B signaling by activating the kinase PKC-? in T cells. |
| 20936779 | 2010 | A human MAP kinase interactome. |
| 20628086 | 2010 | Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study. |
| 20379614 | Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. | |
| 20227368 | 2010 | PP2A T61 epsilon is an inhibitor of MAP4K3 in nutrient signaling to mTOR. |
| More... |
